337 related articles for article (PubMed ID: 489)
1. The neurochemistry of Parkinson's disease: effect of L-dopa therapy.
Lloyd KG; Davidson L; Hornykiewicz O
J Pharmacol Exp Ther; 1975 Dec; 195(3):453-64. PubMed ID: 489
[TBL] [Abstract][Full Text] [Related]
2. Parkinson's disease: from brain homogenate to treatment.
Hornykiewicz O
Fed Proc; 1973 Feb; 32(2):183-90. PubMed ID: 4143953
[No Abstract] [Full Text] [Related]
3. Peripheral and central inhibitors of catechol-O-methyl transferase: effects on liver and brain COMT activity and L-DOPA metabolism.
Brannan T; Prikhojan A; Yahr MD
J Neural Transm (Vienna); 1997; 104(1):77-87. PubMed ID: 9085195
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
[TBL] [Abstract][Full Text] [Related]
5. Serotonergic neurones are not involved in action of L-dopa in Parkinson's disease.
Melamed E; Hefti F; Liebman J; Schlosberg AJ; Wurtman RJ
Nature; 1980 Feb; 283(5749):772-4. PubMed ID: 6101905
[No Abstract] [Full Text] [Related]
6. Comparison of short and long-lasting effects of pargyline on cerebral dopamine metabolism.
Waldmeier PC; Maître L
Naunyn Schmiedebergs Arch Pharmacol; 1976 Aug; 294(2):133-40. PubMed ID: 1012333
[TBL] [Abstract][Full Text] [Related]
7. [Biochemical bases of Parkinson disease].
Colucci d'Amato C; Puccini A; Cristillo A; Vizioli R
Recenti Prog Med; 1984 Oct; 75(10):889-901. PubMed ID: 6151219
[No Abstract] [Full Text] [Related]
8. Favorable effect of catechol-O-methyltransferase inhibition by OR-462 in experimental models of Parkinson's disease.
Lindén IB; Nissinen E; Etemadzadeh E; Kaakkola S; Männistö P; Pohto P
J Pharmacol Exp Ther; 1988 Oct; 247(1):289-93. PubMed ID: 3171977
[TBL] [Abstract][Full Text] [Related]
9. 3-O-methyldopa blocks dopa metabolism in rat corpus striatum.
Reches A; Fahn S
Ann Neurol; 1982 Sep; 12(3):267-71. PubMed ID: 7137962
[TBL] [Abstract][Full Text] [Related]
10. The metabolism of L-DOPA and L-threo-3,4-dihydroxyphenylserine and their effects on monoamines in the human brain: analysis of the intraventricular fluid from parkinsonian patients.
Maruyama W; Naoi M; Narabayashi H
J Neurol Sci; 1996 Jul; 139(1):141-8. PubMed ID: 8836986
[TBL] [Abstract][Full Text] [Related]
11. Role of aromatic L-amino acid decarboxylase for dopamine replacement by genetically modified fibroblasts in a rat model of Parkinson's disease.
Wachtel SR; Bencsics C; Kang UJ
J Neurochem; 1997 Nov; 69(5):2055-63. PubMed ID: 9349551
[TBL] [Abstract][Full Text] [Related]
12. The mechanism of perturbation in monoamine metabolism by L-dopa therapy: in vivo and in vitro studies.
Maruyama W; Naoi M; Takahashi A; Watanabe H; Konagaya Y; Mokuno K; Hasegawa S; Nakahara D
J Neural Transm Gen Sect; 1992; 90(3):183-97. PubMed ID: 1363050
[TBL] [Abstract][Full Text] [Related]
13. Catechol-O-methyltransferase and Parkinson's disease.
Reches A; Fahn S
Adv Neurol; 1984; 40():171-9. PubMed ID: 6695593
[TBL] [Abstract][Full Text] [Related]
14. Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms.
Cumming P; Gjedde A
Synapse; 1998 May; 29(1):37-61. PubMed ID: 9552174
[TBL] [Abstract][Full Text] [Related]
15. The role of the regulatory enzymes of catecholamine synthesis in Parkinson's disease.
Goldstein M; Lieberman A
Neurology; 1992 Apr; 42(4 Suppl 4):8-12; discussion 41-8. PubMed ID: 1350074
[TBL] [Abstract][Full Text] [Related]
16. The significance of 3-O-methyldopa concentrations in the cerebrospinal fluid in the pathogenesis of wearing-off phenomenon in Parkinson's disease.
Tohgi H; Abe T; Kikuchi T; Takahashi S; Nozaki Y
Neurosci Lett; 1991 Oct; 132(1):19-22. PubMed ID: 1787913
[TBL] [Abstract][Full Text] [Related]
17. Striatal L-dopa decarboxylase activity in Parkinson's disease in vivo: implications for the regulation of dopamine synthesis.
Gjedde A; Léger GC; Cumming P; Yasuhara Y; Evans AC; Guttman M; Kuwabara H
J Neurochem; 1993 Oct; 61(4):1538-41. PubMed ID: 8377003
[TBL] [Abstract][Full Text] [Related]
18. The decarboxylation of DOPA in the parkinsonian brain: in vivo studies on an animal model.
Hefti F; Melamed E; Wurtman RJ
J Neural Transm Suppl; 1980; (16):95-101. PubMed ID: 6776238
[TBL] [Abstract][Full Text] [Related]
19. The dopamine hypothesis: an overview of studies with schizophrenic patients.
Haracz JL
Schizophr Bull; 1982; 8(3):438-69. PubMed ID: 6127808
[TBL] [Abstract][Full Text] [Related]
20. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
Hossain MA; Weiner N
J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
